Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Claudia A. McDonald Bøen, Ph.D.
CEO at Arctic Pharma
About the author:
Claudia A. McDonald Bøen is leading the research team at Arctic Pharma AS. Claudia has experience in both academia and industry. Claudia has been involved in designing cancer diagnostic tools, drug development and commercialization of products for scientific use prior to joining Arctic Pharma.
Claudia received her Master of Science degree from San Francisco State University in 2008. Her master studies focused on developing and applying methods for analyzing the glycoproteome in breast cancer cells. That same year Claudia cofounded a proteomics software company, Proteome Solutions. Claudia graduated in 2013 with a PhD in biological chemistry from the University of Michigan in Ann Arbor. Claudia’s doctoral work focused on studying the mechanism of flavin-dependent enzymes by kinetics and spectroscopy.
Posts by Claudia A. McDonald Bøen, Ph.D.
Posted on March 31st, 2017 in Pharma R&D
Just as some members of our team are going off on parental leave to grow their families, our Arctic Pharma research family is also getting bigger. We have recently expanded the Arctic team by bringing on board three very talented scientists. (more…)
Posted on March 29th, 2017 in Pharma R&D
Our biochemistry project leader, Steffi Lundvall, recently gave a lecture at Ullern videregående skole, the local high school, located on the floor below our research facilities. (more…)
Posted on February 15th, 2017 in Pharma R&D
2017 is well under way, and Arctic Pharma has big plans for the year. For one thing, we will be focused on submitting our provisional patents. We will also be working on performing toxicology studies on our best compounds. (more…)
Posted on December 15th, 2016 in Pharma R&D
At a high level, we at Arctic Pharma are working on innovative therapies for cancer that have minimal side effects. More specifically, we are targeting certain enzymes that are up-regulated in cancer cell metabolism using inhibitors that we have designed. (more…)